Volume 11, Number 6—June 2005
Research
Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance
David J. Farrell*
, Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
, Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
Table 2
Proportion of erythromycin-resistant Streptococcus pneumoniae isolates collected from years 1 to 3 of the PROTEKT US study with the dual mef(A)+erm(B) genotype according to patient age
| Patient age (y) | No. erm(B)+mef(A)–positive/no. erythromycin-resistant (%) |
||
|---|---|---|---|
| Year 1 | Year 2 | Year 3 | |
| 0–2 | 88/825 (10.7) | 118/640 (18.4) | 170/710 (23.9) |
| 3–14 | 52/388 (13.4) | 47/365 (12.9) | 84/409 (20.5) |
| 15–64 | 98/1,106 (8.9) | 95/972 (9.8) | 151/1,173 (12.9) |
| >64 | 58/727 (8.0) | 70/755 (9.3) | 98/794 (12.3) |
| Not specified |
8/87 (9.2) |
5/61 (8.2) |
17/91 (18.7) |
| Total | 304/3,133 (9.7) | 335/2,793 (12.0) | 520/3,177 (16.4) |
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.